Month: August 2020

“The strong market during the first quarter continued into the second quarter of 2020, which has resulted in the strongest half-year since 2008. TORM achieved a profit before tax of USD 128m for the first six months of 2020. I am pleased that TORM’s strong financial position allows us to distribute a total of USD 63m, or DKK 397m, in dividends to our shareholders for the half-year. With recent sales of seven older vessels at attractive prices, we have continued our ongoing fleet renewal activities, enabling TORM to actively pursue attractive opportunities in the market as they arise,” says Executive Director Jacob Meldgaard and adds: “Further, I am pleased that at this point in the third quarter of 2020, TORM’s solid operational platform has secured strong bookings that indicate a positive result for the whole quarter.”In the second quarter...

“Det stærke marked gennem første kvartal fortsatte ind i andet kvartal 2020, hvilket har resulteret i det bedste halvårsresultat siden 2008. TORM har opnået et overskud før skat på USD 128 mio. for de første seks måneder af 2020. Jeg er tilfreds med, at TORMs stærke finansielle situation gør det muligt for os at udbetale et samlet udbytte på USD 63 mio., svarende til DKK 397 mio., til vores aktionærer for halvåret. Med de seneste salg af syv ældre skibe til attraktive priser har vi fortsat vores løbende flådefornyelse og positioneret os til at forfølge de attraktive muligheder, der måtte opstå i markedet,” udtaler Executive Director Jacob Meldgaard og tilføjer: ”Jeg er ligeledes tilfreds med, at TORMs solide operationelle platform også i tredje kvartal til dato har sikret en stærk indtjening, hvilket indikerer en positiv bundlinje for...

Sidetrade (Euronext Growth : ALBFR.PA), plateforme d’Intelligence Artificielle dédiée à l’accélération du revenu et du cash-flow des entreprises, annonce avoir conclu un nouveau contrat de liquidités conforme à la charte Amafi avec Louis Capital Partners, qui prend effet le 17 août 2020.Bilan du contrat de liquidité conclu avec Gilbert DupontLe 14 août 2020 au soir, Sidetrade et la société de Bourse Gilbert Dupont ont mis fin à leur contrat de liquidité. A cette date, les moyens qui figuraient au compte de liquidité étaient :            Nombre d’actions : 2 855            Solde en espèces du compte de liquidité : 170 554,70 €Il est rappelé que lors du bilan semestriel du 30 juin 2020 (cf. communiqué du 2 juillet 2020), les moyens suivants figuraient au compte de liquidité :            Nombre d’actions : 2 476            Solde en espèces...

Phase 2b clinical trial in collaboration with Professor Shabir Madhi and Wits UniversityBill & Melinda Gates Foundation providing $15 million grant toward trialMature trial infrastructure along with significant levels of seasonal transmission may allow for rapid efficacy evaluationGAITHERSBURG, Md., Aug. 17, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the beginning of a Phase 2b clinical trial in South Africa to evaluate the efficacy of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. Dr. Shabir Madhi, Professor of Vaccinology at Wits University, will lead the clinical trial, which is supported in part by a $15 million grant from the Bill & Melinda Gates Foundation. NVX‑CoV2373 is a stable,...

HAIFA, Israel, Aug. 17, 2020 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today its subsidiary, Pluristem Ltd., has signed a non-binding Memorandum of Understanding (MOU) with the United Arab Emirates-based Abu Dhabi Stem Cells Center (ADSCC), a specialist healthcare center focused on cell therapy and regenerative medicine. Executives from both companies took part in a signing ceremony held via video conference between Israel and the UAE. The aim of the collaboration is to capitalize on each company’s respective areas of expertise in cell therapies to deliver regenerative medicine for the benefit not only of the citizens of the UAE and Israel, but for humanity as a whole. The collaboration...

Company announcement no 2020-10                              17 August 2020Interim Report 2020Very strong start to the year disrupted in mid-March by coronavirus – organic growth of -27% in H1Strong recovery towards end of H1 has continued after the reporting periodMaterial cost containment in response to coronavirus driving -14% organic growth in OPEX in H1EBIT of DKK -193 million before net positive EPOS one-offs of DKK 307 millionNew outlook: 5-15% revenue growth in local currencies in H2 (including EPOS)Group revenue in the first half-year amounted to DKK 6,078 million, corresponding to a decrease of 17% compared to last year. Organic growth contributed -27 percentage points, whereas acquisitions added 9 percentage points, including 7 percentage points due to revenue generated in EPOS. Exchange rate effects contributed close to 0 percentage...

Selskabsmeddelelse no 2020-10                                            17. august 2020Halvårsrapport 2020Meget stærk start på året afbrudt af coronavirus i midten af marts – organisk vækst på -27 % i H1Den stærke bedring hen imod slutningen af H1 er fortsat efter rapporteringsperiodenBetydeligt omkostningsfokus som reaktion på coronavirus har drevet -14 % organisk vækst i OPEX i H1EBIT på DKK -193 mio. før netto positive engangseffekter relateret til EPOS på DKK 307 mio.Nye forventninger: 5-15 % omsætningsvækst i lokal valuta i H2 (inkl. EPOS)Koncernomsætningen nåede i første halvår DKK 6.078 mio. svarende til en nedgang på 17 % i forhold til sidste år. Den organiske vækst bidrog med -27 procentpoint, mens akkvisitioner bidrog med 9 procentpoint, hvoraf 7 procentpoint kan henføres til omsætning realiseret i EPOS. Valutakurseffekter bidrog...

Sanofi to acquire Principia Biopharma Further strengthens core R&D areas of autoimmune and allergic diseasesProvides full control of brain-penetrant BTK inhibitor SAR442168 in multiple sclerosis (MS), making commercialization more efficient and eliminating future royalty paymentsAllows expansion of SAR442168 development program into other central nervous system diseases and therapeutic areasAdds clinically advanced oral BTK inhibitor rilzabrutinib with potential across a range of immunology and inflammation indications, complementing Sanofi’s existing R&D pipelinePARIS and SOUTH SAN FRANCISCO, Calif. – August 17, 2020 – Sanofi and Principia Biopharma Inc. (NASDAQ: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, entered into a definitive agreement under which Sanofi...

Sanofi va acquérir Principia BiopharmaRenforcement des principaux domaines de R&D dans les maladies auto-immunes et allergiques.Contrôle intégral de l’inhibiteur BTK à pénétration cérébrale SAR442168 dans le traitement de la sclérose en plaques (SEP) qui permettra une commercialisation plus efficace et supprime le versement de futures redevances.Expansion du programme de développement du SAR442168 dans le traitement d’autres maladies du système nerveux central et dans d’autres domaines thérapeutiques.Ajout au portefeuille de l’inhibiteur BTK par voie orale rilzabrutinib au stade de développement avancé pour le traitement potentiel de plusieurs maladies immuno-inflammatoires, en complément du portefeuille de R&D actuel de Sanofi.PARIS et SAN FRANCISCO SUD (Californie) – Le 17 août 2020 – Sanofi et Principia Biopharma Inc. (NASDAQ :...

EfTEN Real Estate Fund III AS acquired through its subsidiary Rutkausko UAB in Vilnius the Rutkausko office building where the anchor tenant is international IT firm Atea. The transaction was closed on Friday, 14 August 2020. Total value of the transaction is 11.8 million euros, of which 4.5 million euros is financed from uninvested equity of EfTEN Real Estate Fund III AS and 7.3 million euros by SEB bank with loan margin of 2,1%. Average net entrance yield of the project is 7.1%. The property was sold by Sonex Consulting UAB. With the current transaction all equity in the fund is fully invested. “We decided to go against the flow in a time where transactions with commercial properties are uncommon and expand the portfolio of EfTEN Real Estate Fund III AS with a modern office building in Vilnius with a strong anchor tenant. After meticulously...